DYRK1A As A Novel Target For Glioblastoma Therapies
Funder
National Health and Medical Research Council
Funding Amount
$620,294.00
Summary
Glioblastoma is a form of brain cancer that is currently incurable. We have discovered that switching-off an enzyme called DYRK1A (using ‘DYRK1A inhibitors’) kills glioblastoma cells. This therapeutic advantage is even greater when combined with drugs approved for other cancers. This project will develop new DYRK1A inhibitors and examine a novel combination treatment for glioblastoma patients. This could initiate a novel therapy that could significantly extend patients’ lives.
Investigations into the antibacterial mechanism of action of cannabidiol. This project aims to understand how the compound cannabidiol is able to kill bacteria by examining its interactions with bacteria from a genetic and molecular level. This research is critical, because future development of cannabidiol and design of improved analogs is predicated on knowing how it works. Expected outcomes include the first detailed understanding of how cannabidiol interacts with bacteria. This should lead ....Investigations into the antibacterial mechanism of action of cannabidiol. This project aims to understand how the compound cannabidiol is able to kill bacteria by examining its interactions with bacteria from a genetic and molecular level. This research is critical, because future development of cannabidiol and design of improved analogs is predicated on knowing how it works. Expected outcomes include the first detailed understanding of how cannabidiol interacts with bacteria. This should lead to significant benefits, including high impact publications, additional collaborations with industrial partner Botanix, and a new class of antibiotics to overcome antibiotic resistance.Read moreRead less